



HELIX

biopharma

HELIX LOOP

Your inside track on Helix BioPharma – October 2025

Welcome to the third edition of the **Helix Loop**— your bi-monthly update on the people, progress, and priorities driving Helix BioPharma forward.

As we move into the final quarter of 2025, our focus is laser-sharp: advancing L-DOS47 toward its next clinical milestone and strengthening our financial position to support continued growth. The momentum built over the summer is translating into tangible progress across science and strategy.

Thank you for continuing to follow our journey. Every advancement reinforces our commitment to delivering innovative, clinically meaningful solutions for people battling hard-to-treat cancers.

Inside this issue:

-  Pipeline highlights
-  Financial / Financing updates
-  Traction

Pipeline Highlights

- L-DOS47 Phase IB in NSCLC: Following our constructive interaction with the FDA in early August 2025, we now are finalizing the clinical protocol for LDOS007, our planned Phase IB/Randomized Phase 2 study to assess L-DOS47 in combination with pembrolizumab in non-small cell lung cancer (NSCLC). The study is designed to determine the optimal biological dose through extensive biomarker analysis, including the use of AI to enhance data interpretation and dose selection.

Financial and Financing Updates

- On October 29, 2025, [we released our audited financial results for the fiscal year ended July 31, 2025](#). Helix reported a net loss of \$5.2 million for the fiscal year ended July 31, 2025—an improvement from \$9.3 million in 2024—reflecting disciplined cost management and a sharpened strategic focus on L-DOS47. Research and development expenses decreased by 40%, and operating costs by 43%, following the completion of our pancreatic study, closure of non-core programs, and streamlining of operations. Over the past year, we strengthened our capital structure through two private placements and the Laevoroc asset acquisition, while also refining our financing strategy to support upcoming clinical milestones.
- In September 2025, [we announced that we would not proceed](#) with the previously planned equity draw-down facility with GEM Global Yield. This decision reflects our commitment to pursuing financing options that align with our long-term strategy and protect shareholder value.
- We are currently in advanced discussions for a private placement, while institutional investors are conducting due diligence in our data room. These ongoing discussions reflect growing interest in Helix's focused strategy and clinical direction, and we remain committed to securing financing that supports our next phase of growth on shareholder-friendly terms.
- NASDAQ uplisting anticipated in Q1 2026.

Traction

- On September 16, 2025, CEO Dr. Thomas Mehrling [presented at the Q3 Investor Summit Virtual](#), highlighting Helix's upcoming Phase Ib/Randomized Phase II study of L-DOS47 in combination with pembrolizumab and the Company's planned NASDAQ uplisting—key milestones that underscore our growth strategy and increasing visibility among global investors.



Request a Meeting

We're building value—and momentum. If you're an investor aligned with our vision, we'd love to connect.

[Request a Meeting](#)

If you wish to unsubscribe from our newsletter, click [here](#)